Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ELAN
2017-000236-34Phase 4Completed
- Sponsor
- Inselspital
- Start
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of rivaroxaban, dabigatran, edoxaban and apixaban in Atrial fibrillation (AFib) and ischemic stroke (2 arms), sponsored by Inselspital. Primary endpoint: Primary composite outcome at 30 ± 3 days. Started Dec 2018; status: completed.
02
Drugs
rivaroxabandabigatranedoxabanapixaban
03
Conditions
Atrial fibrillation (AFib)ischemic stroke
Beyond the preview
Go deeper on 2017-000236-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-000236-34.